publication . Article . 2019

Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults.

Hao Hu; Ke-Liang Chen; Ya-Nan Ou; Xi-Peng Cao; Shi-Dong Chen; Mei Cui; Qiang Dong; Lan Tan; Jin-Tai Yu; null Alzheimer�s Disease Neuroimaging Initiative;
Open Access
  • Published: 01 Sep 2019 Journal: Aging, volume 11 (eissn: 1945-4589, Copyright policy)
  • Publisher: Impact Journals, LLC
Abstract
Previous studies demonstrated that plasma neurofilament light chain (NFL) played important predictive roles in disease progression and neurodegeneration in the preclinical phase of familial Alzheimer’s disease (AD). However, whether plasma NFL has the same predictive roles in sporadic AD is still unclear. In this study, 243 cognitively normal (CN) participants from the ADNI database were divided into two subgroups (CN- and CN+) according to CSF Aβ or AV45-PET. Associations of baseline plasma NFL concentrations or rate of change in plasma NFL with longitudinal data on other biomarkers were tested by multivariate linear mixed effects models (LMEMs). Results showed...
Subjects
free text keywords: Pathology, medicine.medical_specialty, medicine, Neurodegeneration, medicine.disease, Clinical progression, business.industry, business, Neurofilament light, Research Paper, neurofilament light chain, Alzheimer’s disease, biomarker, prediction
Related Organizations
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
Download fromView all 2 versions
Aging
Article
Provider: UnpayWall
Aging
Article . 2019
Provider: Crossref
25 references, page 1 of 2

1 Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, et al, and Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects.Ann Neurol. 2009; 65:403–13. 10.1002/ana.21610 19296504 [OpenAIRE] [PubMed] [DOI]

2 Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.Neurology. 2006; 67:446–52. 10.1212/01.wnl.0000228230.26044.a4 16894106 [OpenAIRE] [PubMed] [DOI]

3 Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly.Arch Neurol. 2008; 65:1509–17. 10.1001/archneur.65.11.1509 19001171 [OpenAIRE] [PubMed] [DOI]

4 Roeback JR Jr, Hla KM, Chambless LE, Fletcher RH. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial.Ann Intern Med. 1991; 115:917–24. 10.7326/0003-4819-115-12-917 1683196 [OpenAIRE] [PubMed] [DOI]

5 Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM. CSF biomarker levels in early and late onset alzheimer’s disease.Neurobiol Aging. 2009; 30:1895–901. 10.1016/j.neurobiolaging.2008.02.007 18403055 [OpenAIRE] [PubMed] [DOI]

6 Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, et al, and Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease.Alzheimers Dement. 2018; 14:535–62. 10.1016/j.jalz.2018.02.018 29653606 [OpenAIRE] [PubMed] [DOI]

7 Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A. Neurochemical aftermath of amateur boxing.Arch Neurol. 2006; 63:1277–80. 10.1001/archneur.63.9.1277 16966505 [OpenAIRE] [PubMed] [DOI]

8 Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, et al, and Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease.Nat Med. 2019; 25:277–83. 10.1038/s41591-018-0304-3 30664784 [OpenAIRE] [PubMed] [DOI]

9 Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, Hagen CE, van Harten AC, Knopman DS, Jack CR Jr, Petersen RC, Mielke MM. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.JAMA Neurol. 2019; 76:187–193. 10.1001/jamaneurol.2018.3459 30419087 [OpenAIRE] [PubMed] [DOI]

10 Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer’s Disease Neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.JAMA Neurol. 2017; 74:557–66. 10.1001/jamaneurol.2016.6117 28346578 [OpenAIRE] [PubMed] [DOI]

11 Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade.Lancet Neurol. 2010; 9:119–28. 10.1016/S1474-4422(09)70299-6 20083042 [OpenAIRE] [PubMed] [DOI]

12 Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.J Neurol Sci. 2005; 233:183–98. 10.1016/j.jns.2005.03.015 15896809 [OpenAIRE] [PubMed] [DOI]

13 Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.Neuron. 2016; 91:494–96. 10.1016/j.neuron.2016.07.007 27477021 [PubMed] [DOI]

14 Buerger K, Ewers M, PirttiläT, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease.Brain. 2006; 129:3035–41. 10.1093/brain/awl269 17012293 [OpenAIRE] [PubMed] [DOI]

15 Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, and Alzheimer’s Disease Neuroimaging Initiative. Seri al PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease.Brain. 2009; 132:1355–65. 10.1093/brain/awp062 19339253 [OpenAIRE] [PubMed] [DOI]

25 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2019

Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults.

Hao Hu; Ke-Liang Chen; Ya-Nan Ou; Xi-Peng Cao; Shi-Dong Chen; Mei Cui; Qiang Dong; Lan Tan; Jin-Tai Yu; null Alzheimer�s Disease Neuroimaging Initiative;